Genmab to acquire Merus for $8 billion, expanding its late-stage oncology pipeline and preparing for the loss of exclusivity for its key drug Darzalex IV.
Supreme Court to hear U.S. compensation claims for Cuban confiscated property, potentially easing the way for U.S. companies to seek damages.
Genmab to acquire Merus for $8 billion, expanding its late-stage oncology pipeline and preparing for the loss of exclusivity for its key drug Darzalex IV.
Supreme Court to hear U.S. compensation claims for Cuban confiscated property, potentially easing the way for U.S. companies to seek damages.